文献速递特殊人群用药肝肾功能剂量调整

基于群体药代动力学评估5月龄至18岁HIV感染儿童拉米夫定剂量

Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis.
PubMed 文献 · Br J Clin Pharmacol · 2017-02-14

该研究利用群体药代动力学模型分析180例5月龄至18岁HIV感染儿童的拉米夫定数据,发现体重是表观清除率和分布容积的最佳预测因素。体重>14 kg儿童中94.5%达到成人目标AUC0-24h,而<14 kg儿童仅35.8%达标;建议体重<14 kg儿童剂量从8 mg kg-1 day-1增至10 mg kg-1 day-1。

要点

  • 体重是拉米夫定表观清除率和分布容积的最佳预测因素
  • 体重>14 kg儿童94.5%达到成人目标AUC0-24h
  • 体重<14 kg儿童建议剂量增至10 mg kg-1 day-1

核心结论

  • 体重最佳预测拉米夫定表观清除率和分布容积的发育变化。
  • 体重<14 kg的5月龄至18岁儿童,若以成人AUC0-24h为目标,剂量应从8 mg kg-1 day-1增至10 mg kg-1 day-1。

研究设计与样本

  • 群体药代动力学建模(NONMEM)使用两个建模数据集和两个外部数据集,共180例(年龄0.4-18岁,体重3.4-60.5 kg),2061个样本(每儿童中位12个),每日口服剂量60-300 mg(3.9-17.6 mg kg-1)。

主要发现

  • 二室模型联合序列零级和一级吸收最佳描述数据。
  • 中位体重16.6 kg个体的表观清除率和中央分布容积分别为13.2 l h-1(%RSE 4.2%)和38.9 l(7.0%)。
  • 体重作为协变量对表观清除率和分布容积的幂函数指数分别为0.506(20.2%)和0.489(32.3%)。
  • 外部评估支持最终模型的预测能力。
  • 体重>14 kg和<14 kg儿童达到目标AUC0-24h的比例分别为94.5%和35.8%。

关键数值与推荐

  • 成人目标稳态AUC0-24h为8.9 mg·h l-1。
  • 体重<14 kg儿童推荐剂量从8 mg kg-1 day-1增至10 mg kg-1 day-1(若以成人AUC0-24h为目标)。

临床怎么用

  • 对体重<14 kg的5月龄至18岁HIV感染儿童,可考虑将拉米夫定剂量增至10 mg kg-1 day-1以达成人目标AUC0-24h。
  • 体重>14 kg儿童按8 mg kg-1 day-1剂量可使94.5%达到目标AUC0-24h。

局限性

  • 需未来纳入静脉给药拉米夫定数据以分析体重是否影响生物利用度、清除率和/或分布容积。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: The objectives of this study were to characterize age-related changes in lamivudine pharmacokinetics in children and evaluate lamivudine exposure, followed by dose recommendations for subgroups in which target steady state area under the daily plasma concentration-time curve (AUC0-24h ) is not reached. METHODS: Population pharmacokinetic modelling was performed in NONMEM using data from two model-building datasets and two external datasets [n = 180 (age 0.4-18 years, body weight 3.4-60.5 kg); 2061 samples (median 12 per child); daily oral dose 60-300 mg (3.9-17.6 mg kg-1 )]. Steady state AUC0-24h was calculated per individual (adult target 8.9 mg·h l-1 ). RESULTS: A two-compartment model with sequential zero order and first order absorption best described the data. Apparent clearance and central volume of distribution (% RSE) were 13.2 l h-1 (4.2%) and 38.9 l (7.0%) for a median individual of 16.6 kg, respectively. Bodyweight was identified as covariate on apparent clearance and volume of distribution using power functions (exponents 0.506 (20.2%) and 0.489 (32.3%), respectively). The external evaluation supported the predictive ability of the final model. In 94.5% and 35.8% of the children with a body weight >14 kg and <14 kg, respectively, the target AUC0-24h was reached. CONCLUSION: Bodyweight best predicted the developmental changes in apparent lamivudine clearance and volume of distribution. For children aged 5 months-18 years with a body weight <14 kg, the dose should be increased from 8 to 10 mg kg-1 day-1 if the adult target for AUC0-24h is aimed for. In order to identify whether bodyweight influences bioavailability, clearance and/or volume of distribution, future analysis including data on intravenously administered lamivudine is needed.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Janssen EJH, Bastiaans DET, Välitalo PAJ, et al. Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis. Br J Clin Pharmacol. 2017. PMID: 28079918. doi:10.1111/bcp.13227

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。